Table 2 Main characteristics of bisphosphonates (BPs)
From: Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Type of BPs | Relative potency | Average dose administered (mg) | Bone absorption rate | Average dose deposited in bone (mg) | Weight dose deposited/1000 |
|---|---|---|---|---|---|
Pamidronate | 100 | 142,750 | 1% (PO) | 1427.5 | 142.75 |
300 | 70% (IV) | 210 | 21 | ||
Alendronate | 1000 | 17,633 | 1% (PO) | 176 | 176 |
Ibandronate | 10,000 | 6900 | 1% (PO) | 69 | 690 |
51.43 | 70% (IV) | 36 | 360.01 | ||
Risendronate | 20,000 | 9861.25 | 1% (PO) | 98.61 | 1972.25 |
Zoledronate | 100,000 | 62.67 | 70% (IV) | 43.87 | 4386.90 |